Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1169) 1169
Newspaper Article (1088) 1088
Book / eBook (656) 656
Magazine Article (61) 61
Report (59) 59
Book Review (54) 54
Dissertation (40) 40
Patent (35) 35
Publication (35) 35
Book Chapter (31) 31
Trade Publication Article (20) 20
Reference (14) 14
Government Document (11) 11
Newsletter (8) 8
Transcript (5) 5
Archival Material (3) 3
Conference Proceeding (1) 1
Paper (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
history (171) 171
historia (66) 66
humans (51) 51
history and criticism (50) 50
criticism and interpretation (43) 43
male (41) 41
annual reports (36) 36
financial statements (36) 36
index medicus (36) 36
studies (36) 36
aged (35) 35
politics and government (32) 32
travel (31) 31
middle aged (29) 29
adult (28) 28
female (27) 27
human necessities (25) 25
hygiene (25) 25
medical or veterinary science (25) 25
preparations for medical, dental, or toilet purposes (25) 25
spanish literature (25) 25
analysis (24) 24
bibliography (24) 24
religion (23) 23
analisis (21) 21
art (21) 21
french literature (21) 21
aspectos sociales (20) 20
italy (20) 20
oncology (20) 20
catalogs (19) 19
literatura española (19) 19
research (19) 19
biography (18) 18
music (18) 18
anthropology (17) 17
cancer (17) 17
chemistry (17) 17
chemotherapy (17) 17
italy politics and government (17) 17
metastasis (17) 17
sociology (17) 17
aged, 80 and over (16) 16
metallurgy (16) 16
specific therapeutic activity of chemical compounds ormedicinal preparations (16) 16
crítica e interpretación (15) 15
prednisone (15) 15
treatment outcome (15) 15
1900-1999 (14) 14
colonization (14) 14
literature (14) 14
management (14) 14
organic chemistry (14) 14
poetry (14) 14
political science (14) 14
prostate cancer (14) 14
civilization (13) 13
critica, interpretacion, etc (13) 13
exhibitions (13) 13
historia y crítica (13) 13
investigacion cientifica (13) 13
manuscripts (13) 13
architecture (12) 12
church history (12) 12
españa (12) 12
heterocyclic compounds (12) 12
italian literature (12) 12
obras (12) 12
science (12) 12
antineoplastic combined chemotherapy protocols - therapeutic use (11) 11
archaeology (11) 11
care and treatment (11) 11
disease-free survival (11) 11
historiography (11) 11
italian language (11) 11
politics (11) 11
social conditions (11) 11
storia (11) 11
survival analysis (11) 11
women (11) 11
abiraterone acetate (10) 10
dictionaries (10) 10
economic conditions (10) 10
fiction (10) 10
intellectual life (10) 10
painting, italian (10) 10
política y gobierno (10) 10
prostatic neoplasms, castration-resistant - drug therapy (10) 10
quinolones - administration & dosage (10) 10
survival (10) 10
survival rate (10) 10
urology & nephrology (10) 10
arte (9) 9
biographies (9) 9
books (9) 9
cervantes saavedra, miguel de (9) 9
construction industry (9) 9
corticosteroids (9) 9
docetaxel (9) 9
early works to 1800 (9) 9
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Robarts - Stacks (282) 282
UTL at Downsview - May be requested (155) 155
Collection Dvlpm't (Acquisitions) - Vendor file (64) 64
Pontifical Inst. Mediaeval Studies - Library use only (44) 44
UofT at Mississauga - Stacks (18) 18
Art - Library use only (13) 13
St. Michael's College (John M. Kelly) - 3rd Floor (12) 12
Victoria University CRRS - Library use only (10) 10
Music - Stacks (9) 9
Robarts - Storage (9) 9
St. Michael's College (John M. Kelly) - 2nd Floor (9) 9
Collection Dvlpm't (Acquisitions) - Closed Orders (8) 8
Thomas Fisher Rare Book - Rare Book (8) 8
Victoria University E.J. Pratt - Stacks (8) 8
Pontifical Inst. Mediaeval Studies - Reference (6) 6
Online Resources - Online (5) 5
Trinity College (John W Graham) - Stacks (5) 5
UofT at Scarborough - Stacks (5) 5
Regis College - Stacks (4) 4
Robarts - Reference (4) 4
St. Augustine's Seminary - Stacks (4) 4
Gerstein Science - Stacks (3) 3
Victoria University Emmanuel College - Stacks (3) 3
Architecture Landscape (Shore + Moffat) - Stacks (2) 2
Earth Sciences (Noranda) - Reference (2) 2
Gerstein Science - Reference (2) 2
New College (Ivey) - Stacks (2) 2
Robarts - May be requested in 6-10 wks (2) 2
Royal Ontario Museum - Stacks (2) 2
Art - Reference (1) 1
Art - Stacks (1) 1
Earth Sciences (Noranda) - Library use only (1) 1
Earth Sciences (Noranda) - Stacks (1) 1
Engineering & Comp. Sci. - Stacks (1) 1
Music - Library use only (1) 1
Music - May be requested in 6-10 wks (1) 1
Music - Protected Material (1) 1
OISE - Curriculum Resources (1) 1
OISE - Stacks (1) 1
Pontifical Inst. Mediaeval Studies - Gilson (1) 1
Pontifical Inst. Mediaeval Studies - Guest (1) 1
Pontifical Inst. Mediaeval Studies - Oversize (1) 1
Pontifical Inst. Mediaeval Studies - Stacks (1) 1
Regis College - Storage (1) 1
Robarts - Course Reserves (1) 1
Robarts - In process for Downsview (1) 1
Robarts - Library use only (1) 1
Royal Ontario Museum - Reference (1) 1
Royal Ontario Museum - Reference Desk (1) 1
St. Augustine's Seminary - Missing (1) 1
St. Michael's College (John M. Kelly) - Reference (1) 1
St. Michael's College (John M. Kelly) - Soulerin (1) 1
Thomas Fisher Rare Book - Reference (1) 1
Trinity College (John W Graham) - Reference (1) 1
Trinity College (John W Graham) - Storage (1) 1
Victoria University CRRS - Rare Book (1) 1
Victoria University E.J. Pratt - Library use only (1) 1
Victoria University E.J. Pratt - Reference (1) 1
Victoria University E.J. Pratt - Riese (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (966) 966
Spanish (836) 836
French (646) 646
Danish (449) 449
Italian (344) 344
Portuguese (168) 168
German (65) 65
Latin (52) 52
Dutch (51) 51
Swedish (37) 37
Old French (6) 6
Greek (3) 3
Ancient Greek (2) 2
Norwegian (2) 2
Polish (2) 2
Catalan (1) 1
Chinese (1) 1
Czech (1) 1
Galician (1) 1
Icelandic (1) 1
Japanese (1) 1
Middle (1) 1
Nahuatl (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Author’s Reply to Srinivas: “Modeling the Relationship Between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer”
by Xu, Steven and De Porre, Peter
Clinical Pharmacokinetics, ISSN 0312-5963, 02/2017, Volume 56, Issue 2, pp. 213 - 214
Journal Article
Details down arrow
2. Full Text Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
by Ryan, Charles J, Prof and Smith, Matthew R, Prof and Fizazi, Karim, Prof and Saad, Fred, Prof and Mulders, Peter F A, Prof and Sternberg, Cora N, MD and Miller, Kurt, Prof and Logothetis, Christopher J, Prof and Shore, Neal D, MD and Small, Eric J, Prof and Carles, Joan, MD and Flaig, Thomas W, MD and Taplin, Mary-Ellen, MD and Higano, Celestia S, Prof and de Souza, Paul, Prof and de Bono, Johann S, Prof and Griffin, Thomas W, MD and De Porre, Peter, MD and Yu, Margaret K, MD and Park, Youn C, PhD and Li, Jinhui, PhD and Kheoh, Thian, PhD and Naini, Vahid, PharmD and Molina, Arturo, MD and Rathkopf, Dana E, MD and COU-AA-302 Investigators
Lancet Oncology, ISSN 1470-2045, 2015, Volume 16, Issue 2, pp. 152 - 160
Summary Background Abiraterone acetate plus prednisone significantly improved radiographic progression-free survival compared with placebo plus prednisone in... 
Hematology, Oncology and Palliative Medicine | MITOXANTRONE | CABAZITAXEL | ONCOLOGY | DOCETAXEL | ENZALUTAMIDE | Bone Neoplasms - mortality | Prognosis | Double-Blind Method | Follow-Up Studies | Humans | Androstenes - therapeutic use | Antineoplastic Combined Chemotherapy Protocols | Bone Neoplasms - secondary | Male | Survival Rate | Prostatic Neoplasms, Castration-Resistant - drug therapy | Disease Progression | Prostatic Neoplasms, Castration-Resistant - pathology | Antineoplastic Agents, Hormonal - therapeutic use | Aged | Prostatic Neoplasms, Castration-Resistant - mortality | Bone Neoplasms - drug therapy | Neoplasm Staging | Prednisone - therapeutic use | Chemotherapy | Corticosteroids | Analysis | Prednisone | Metastasis | Prostate cancer | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
by Fizazi, Karim and Tran, NamPhuong and Fein, Luis and Matsubara, Nobuaki and Rodriguez-Antolin, Alfredo and Alekseev, Boris Y and Özgüroğlu, Mustafa and Ye, Dingwei and Feyerabend, Susan and Protheroe, Andrew and De Porre, Peter and Kheoh, Thian and Park, Youn C and Todd, Mary B and Chi, Kim N and LATITUDE Investigators and Lund University and Urological cancer, Malmö and Urologisk cancerforskning, Malmö and EpiHealth: Epidemiology for Health and eSSENCE: The e-Science Collaboration and BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation and Lunds universitet
The New England Journal of Medicine, ISSN 0028-4793, 07/2017, Volume 377, Issue 4, pp. 352 - 360
The addition of abiraterone, a drug that blocks endogenous androgen synthesis, to standard androgen-deprivation therapy in patients with newly diagnosed,... 
Androgen Antagonists | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols | Male | Randomized Controlled Trial | Abiraterone Acetate | Journal Article | Prostatic Neoplasms | Clinical Trial, Phase III | Neoplasm Metastasis | Research Support, Non-U.S. Gov't | Survival Analysis | Aged, 80 and over | Adult | Multicenter Study | Aged | Prednisolone | Steroid 17-alpha-Hydroxylase | ANDROGEN-DEPRIVATION THERAPY | MEDICINE, GENERAL & INTERNAL | RECOMMENDATIONS | PLACEBO-CONTROLLED PHASE-3 | SURVIVAL ANALYSIS | CLINICAL-TRIALS | DOUBLE-BLIND | LEUPROLIDE ACETATE | DOCETAXEL | CHEMOTHERAPY | NEOADJUVANT | Prednisolone - adverse effects | Steroid 17-alpha-Hydroxylase - antagonists & inhibitors | Prostatic Neoplasms - radiotherapy | Prednisolone - administration & dosage | Prostatic Neoplasms - surgery | Abiraterone Acetate - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Prostatic Neoplasms - mortality | Abiraterone Acetate - administration & dosage | Neoplasm Metastasis - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Androgen Antagonists - therapeutic use | Androgen Antagonists - administration & dosage | Androgen Antagonists - adverse effects | Prostatic Neoplasms - drug therapy | Androgen suppression therapy | Usage | Prednisone | Research | Prostate cancer | Medical research | Prostate-specific antigen | Clinical trials | Metastasis | Patients | Cancer therapies | Metastases | Androgens | Chemotherapy | Pain | Castration | Medical prognosis | Hypokalemia | Death | Prostate | Abiraterone Acetate/administration & dosage | Prednisolone/administration & dosage | Androgen Antagonists/administration & dosage | Medical and Health Sciences | Medicin och hälsovetenskap | Neoplasm Metastasis/drug therapy | Steroid 17-alpha-Hydroxylase/antagonists & inhibitors | Antineoplastic Combined Chemotherapy Protocols/adverse effects | Klinisk medicin | Clinical Medicine | Prostatic Neoplasms/drug therapy | Cancer and Oncology | Cancer och onkologi
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Converging or Crossing Curves: Untie the Gordian Knot or Cut it? Appropriate Statistics for Non-Proportional Hazards in Decitabine DACO-016 Study (AML)
by Tomeczkowski, Jörg and Lange, Ansgar and Güntert, Andreas and Thilakarathne, Pushpike and Diels, Joris and Xiu, Liang and De Porre, Peter and Tapprich, Christoph
Advances in therapy, 09/2015, Volume 32, Issue 9, p. 854
Among patients with acute myeloid leukemia (AML), the DACO-016 randomized study showed reduction in mortality for decitabine [Dacogen(®) (DAC), Eisai Inc.,... 
United States | Humans | Proportional Hazards Models | Azacitidine - analogs & derivatives | Male | Survival Rate | Statistics as Topic | Leukemia, Myeloid, Acute - mortality | Antimetabolites, Antineoplastic - therapeutic use | Leukemia, Myeloid, Acute - drug therapy | Female | Aged | Azacitidine - therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Author's Reply to Srinivas: "Modeling the Relationship Between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer"
by Xu, Steven and De Porre, Peter
Clinical pharmacokinetics, 02/2017, Volume 56, Issue 2, p. 213
Journal Article
Details down arrow
6. Full Text Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302
by de Bono, Johann S and Smith, Matthew R and Saad, Fred and Rathkopf, Dana E and Mulders, Peter F.A and Small, Eric J and Shore, Neal D and Fizazi, Karim and De Porre, Peter and Kheoh, Thian and Li, Jinhui and Todd, Mary B and Ryan, Charles J and Flaig, Thomas W
European Urology, ISSN 0302-2838, 2016, Volume 71, Issue 4, pp. 656 - 664
Abstract Background Treatment patterns for metastatic castration-resistant prostate cancer (mCRPC) have changed substantially in the last few years. In trial... 
Urology | Subsequent therapy | Treatment patterns | Metastatic castration-resistant prostate cancer | Elderly | Abiraterone acetate | Docetaxel | PLUS PREDNISONE | PLACEBO-CONTROLLED PHASE-3 | SURVIVAL ANALYSIS | DOCETAXEL-BASED CHEMOTHERAPY | ANTITUMOR-ACTIVITY | NAIVE PATIENTS | DOUBLE-BLIND | UROLOGY & NEPHROLOGY | ELDERLY-PATIENTS | CLINICAL ACTIVITY | ENZALUTAMIDE | Carcinoma - drug therapy | Prednisone - administration & dosage | Age Factors | Humans | Middle Aged | Male | Survival Rate | Antineoplastic Agents - therapeutic use | Practice Patterns, Physicians | Prostatic Neoplasms, Castration-Resistant - drug therapy | Prostatic Neoplasms, Castration-Resistant - pathology | Disease-Free Survival | Taxoids - therapeutic use | Abiraterone Acetate - administration & dosage | Neoplasm Metastasis | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged, 80 and over | Adult | Aged | Carcinoma - secondary | Medical colleges | Care and treatment | Chemotherapy | Corticosteroids | Analysis | Prednisone | Metastasis | Prostate cancer | Acetates | Cancer | prostate cancer | Metastatic castration-resistant
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial
by Chi, Kim N and Protheroe, Andrew and Rodríguez-Antolín, Alfredo and Facchini, Gaetano and Suttman, Henrik and Matsubara, Nobuaki and Ye, Zhangqun and Keam, Bhumsuk and Damião, Ronaldo and Li, Tracy and McQuarrie, Kelly and Jia, Bin and De Porre, Peter and Martin, Jason and Todd, Mary B and Fizazi, Karim
The Lancet Oncology, ISSN 1470-2045, 02/2018, Volume 19, Issue 2, pp. 194 - 206
In the LATITUDE trial, addition of abiraterone acetate plus prednisone to androgen deprivation therapy (ADT) improved overall survival compared with placebos... 
SURVIVAL | PLACEBO | PAIN | ONCOLOGY | MEN | SKELETAL-RELATED EVENTS | QUALITY-OF-LIFE | CLINICAL IMPORTANCE | CHEMOTHERAPY | Risk Assessment | Humans | Middle Aged | Kaplan-Meier Estimate | Proportional Hazards Models | Magnetic Resonance Imaging - methods | Tomography, X-Ray Computed - methods | Male | Treatment Outcome | Abiraterone Acetate - therapeutic use | Prostatic Neoplasms, Castration-Resistant - drug therapy | Prostatic Neoplasms, Castration-Resistant - pathology | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Internationality | Neoplasm Invasiveness - pathology | Survival Analysis | Androgen Antagonists - therapeutic use | Quality of Life | Aged | Prostatic Neoplasms, Castration-Resistant - mortality | Neoplasm Staging | Prednisone - therapeutic use | Patient Reported Outcome Measures | Care and treatment | Corticosteroids | Patient outcomes | Analysis | Prednisone | Product development | Metastasis | Prostate cancer | Steroids
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text FGFR-altered, advanced urothelial carcinoma (UC) and response to chemotherapy prior to receiving erdafitinib
by Necchi, Andrea and Siefker-Radtke, Arlene O and Zhong, Bob and Mahadevia, Parthiv Jasvant and Santiago-Walker, Ademi E and De Porre, Peter and Loriot, Yohann
Journal of Clinical Oncology, ISSN 0732-183X, 05/2019, Volume 37, Issue 15_suppl, pp. 4542 - 4542
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Erdafitinib in high-risk patients (pts) with advanced urothelial carcinoma (UC)
by Park, Se Hoon and Loriot, Yohann and Zhong, Bob and Hussain, Syed A and Mahadevia, Parthiv Jasvant and De Porre, Peter and Siefker-Radtke, Arlene O
Journal of Clinical Oncology, ISSN 0732-183X, 05/2019, Volume 37, Issue 15_suppl, pp. 4543 - 4543
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis
by Feyerabend, Susan and Saad, Fred and Li, Tracy and Ito, Tetsuro and Diels, Joris and Van Sanden, Suzy and De Porre, Peter and Roiz, Julie and Abogunrin, Seye and Koufopoulou, Maria and Fizazi, Karim
European Journal of Cancer, ISSN 0959-8049, 11/2018, Volume 103, pp. 78 - 87
Androgen deprivation therapy (ADT) has long been the gold standard for patients with metastatic hormone-sensitive prostate cancer (mHSPC). Clinical trials have... 
Network meta-analysis | Prostatic neoplasms | Abiraterone acetate | Combined modality therapy | Docetaxel | Survival | Quality of life | ONCOLOGY | MEN | ANDROGEN DEPRIVATION THERAPY | Prostatic Neoplasms - pathology | Humans | Male | Abiraterone Acetate - therapeutic use | Disease Progression | Prostatic Neoplasms - mortality | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Docetaxel - pharmacology | Randomized Controlled Trials as Topic | Abiraterone Acetate - pharmacology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Docetaxel - therapeutic use | Prednisone - pharmacology | Quality of Life - psychology | Prednisone - therapeutic use | Prostatic Neoplasms - drug therapy | Antimitotic agents | Prevention | Corticosteroids | Analysis | Development and progression | Prednisone | Metastasis | Hormones | Antineoplastic agents | Prostate cancer | Steroids | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
by Loriot, Yohann and Necchi, Andrea and Park, Se Hoon and Garcia-Donas, Jesus and Huddart, Robert and Burgess, Earle and Fleming, Mark and Rezazadeh, Arash and Mellado, Begoña and Varlamov, Sergey and Joshi, Monika and Duran, Ignacio and Tagawa, Scott T and Zakharia, Yousef and Zhong, Bob and Stuyckens, Kim and Santiago-Walker, Ademi and De Porre, Peter and O’Hagan, Anne and Avadhani, Anjali and Siefker-Radtke, Arlene O and BLC2001 Study Grp and BLC2001 Study Group
The New England Journal of Medicine, ISSN 0028-4793, 07/2019, Volume 381, Issue 4, pp. 338 - 348
Erdafitinib, an inhibitor of fibroblast growth factor receptor, was tested in previously treated patients with advanced urothelial cancer with FGFR... 
MEDICINE, GENERAL & INTERNAL | PHASE-II TRIAL | MULTICENTER | THERAPY | COMPREHENSIVE MOLECULAR CHARACTERIZATION | JNJ-42756493 | CHEMOTHERAPY | Cancer patients | Diagnosis | Bladder cancer | Health aspects | Tyrosine | Creatinine | Fibroblast growth factor | Research & development--R&D | Immune clearance | Metastasis | Gene expression | Kinases | Survival | Metastases | Studies | Chemotherapy | Immunotherapy | Response rates | Antitumor activity | Editorials | Mutation | Full text | Urothelial carcinoma | Fibroblast growth factor receptor 1 | Protein-tyrosine kinase | Drug dosages | Fibroblast growth factor receptors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Impact of Bone-targeted Therapies in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer Patients Treated with Abiraterone Acetate: Post Hoc Analysis of Study COU-AA-302
by Saad, Fred and Shore, Neal and Van Poppel, Hendrik and Rathkopf, Dana E and Smith, Matthew R and de Bono, Johann S and Logothetis, Christopher J and de Souza, Paul and Fizazi, Karim and Mulders, Peter F.A and Mainwaring, Paul and Hainsworth, John D and Beer, Tomasz M and North, Scott and Fradet, Yves and Griffin, Thomas A and De Porre, Peter and Londhe, Anil and Kheoh, Thian and Small, Eric J and Scher, Howard I and Molina, Arturo and Ryan, Charles J
European Urology, ISSN 0302-2838, 2015, Volume 68, Issue 4, pp. 570 - 577
Abstract Background Metastatic castration-resistant prostate cancer (mCRPC) often involves bone, and bone-targeted therapy (BTT) has become part of the overall... 
Urology | Bone-targeted therapy | Metastatic castration-resistant prostate cancer | Chemotherapy-naïve | Abiraterone acetate | SURVIVAL | PLACEBO | Chemotherapy-naive | PHASE-3 | SKELETAL COMPLICATIONS | ANDROGEN-DEPRIVATION THERAPY | ZOLEDRONIC ACID | PREDNISONE | RECOMMENDATIONS | MEN | UROLOGY & NEPHROLOGY | QUALITY-OF-LIFE | Bone Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Bone Neoplasms - secondary | Male | Prostatic Neoplasms, Castration-Resistant - pathology | Antineoplastic Agents, Hormonal - adverse effects | Clinical Trials, Phase III as Topic | Multicenter Studies as Topic | Time Factors | Antineoplastic Agents, Hormonal - therapeutic use | Retrospective Studies | Bone Neoplasms - drug therapy | Odds Ratio | Bone Density Conservation Agents - adverse effects | Steroid Synthesis Inhibitors - adverse effects | Risk Factors | Abiraterone Acetate - adverse effects | Kaplan-Meier Estimate | Proportional Hazards Models | Steroid Synthesis Inhibitors - therapeutic use | Bone Density Conservation Agents - therapeutic use | Treatment Outcome | Abiraterone Acetate - therapeutic use | Prostatic Neoplasms, Castration-Resistant - drug therapy | Randomized Controlled Trials as Topic | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Prostatic Neoplasms, Castration-Resistant - mortality | Bisphosphonate-Associated Osteonecrosis of the Jaw - etiology | Prednisone - therapeutic use | Cancer patients | Care and treatment | Chemotherapy | Oncology, Experimental | Analysis | Research | Metastasis | Prostate cancer | Acetates | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13.